Abstract
In Table 5 (page 571), the first mutation listed, “R321G,” should have been “G321R” (GGG > AGG), and its location should have been listed as exon 5. In location key [B8] Genetic testing: privacy vs. notification of potentially affected family members (page 576), the contribution of Rosenthal and Pierce (2) should have been cited, as contained in the reference list herein. To better reflect what we meant, RECOMMENDATION 50 (page 582) should have said “Medical therapy to control PHPT in MEN 2A should be considered in patients with high risk of surgical mortality, limited life expectancies, or persistent or recurrent PHPT after one or more surgical attempts for cure. Grade: C Recommendation.” The MTC Guidelines were officially endorsed by the Canadian Society of Otolaryngology—Head and Neck Surgery (CSOHNS) and the Ukrainian Association of Endocrine Surgeons (UAES) after its official release in June 2009.
We regret the errors on pages 571, 576, and 582, and are grateful for the additional post-publication endorsements.